Citius Oncology entered into an exclusive distribution agreement with Er-Kim to expand international access to Lymphir (denileukin diftitox-cxdl) in Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia ...

ReAlta Life Sciences appointed Howard Berman, PhD as executive chairman of its board of directors. Top drug regulator Richard ...

SAN FRANCISCO, Sept. 22, 2025 /PRNewswire/ -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers ...

Spectrum Pharmaceuticals, Inc., et al., has been ongoing in the Southern District of New York since late 2022. It alleges that Spectrum repeatedly assured investors that its cancer treatment drug, ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates ...

SAN FRANCISCO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- A federal court has reopened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action, setting a new deadline of ...

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Spectrum's Pinnacle Study of poziotinib for the treatment of lung cancer was less positive ...

SAN FRANCISCO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- On August 4, 2025, the court overseeing the pending securities class action styled Christiansen v. Spectrum Pharmaceuticals, Inc., et al., No.

View all available purchase options and get full access to this article. Supported by Damon Runyon Foundation, V Foundation for Cancer Research, and Sabin Family Foundation (X.L.); NIH/NCI P30CA016672 ...

Four months after calling for the resignation of four board members from Assertio Holdings, New York investment advisory firm Buxton Helmsley Group has flipped its long equity position into a short ...

Spectrum Pharmaceuticals (SPPI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago. These ...

After laying off most of its staff in recent years and suffering an FDA rejection, Spectrum Pharmaceuticals is cashing out. In an agreement unveiled Tuesday, another drugmaker, Assertio Holdings, said ...